+

WO2004066949A3 - Oligonucleotides anti-sens inhibant l'expression du hif-1 - Google Patents

Oligonucleotides anti-sens inhibant l'expression du hif-1 Download PDF

Info

Publication number
WO2004066949A3
WO2004066949A3 PCT/US2004/002344 US2004002344W WO2004066949A3 WO 2004066949 A3 WO2004066949 A3 WO 2004066949A3 US 2004002344 W US2004002344 W US 2004002344W WO 2004066949 A3 WO2004066949 A3 WO 2004066949A3
Authority
WO
WIPO (PCT)
Prior art keywords
hif
inhibit expression
antisense oligonucleotides
cell lines
cancer cell
Prior art date
Application number
PCT/US2004/002344
Other languages
English (en)
Other versions
WO2004066949A2 (fr
WO2004066949A8 (fr
Inventor
Heejeong Yoon
Lingjun Mao
Young Bok Lee
Chang-Ho Ahn
Xiaoming Jiang
Original Assignee
Rexahn Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Corp filed Critical Rexahn Corp
Priority to AU2004207576A priority Critical patent/AU2004207576B8/en
Priority to DE602004022921T priority patent/DE602004022921D1/de
Priority to CA2513398A priority patent/CA2513398C/fr
Priority to EP04706034A priority patent/EP1601325B1/fr
Priority to AT04706034T priority patent/ATE441710T1/de
Priority to BR0407070-4A priority patent/BRPI0407070A/pt
Priority to JP2006503098A priority patent/JP4546454B2/ja
Publication of WO2004066949A2 publication Critical patent/WO2004066949A2/fr
Publication of WO2004066949A8 publication Critical patent/WO2004066949A8/fr
Publication of WO2004066949A3 publication Critical patent/WO2004066949A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne de nouveaux composés oligonucléotidiques anti-sens, RX-0047 et RX-0149, qui inhibent l'expression du HIF-1 et induisent également une cytotoxicité dans plusieurs lignées cellulaires cancéreuses.
PCT/US2004/002344 2003-01-28 2004-01-28 Oligonucleotides anti-sens inhibant l'expression du hif-1 WO2004066949A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2004207576A AU2004207576B8 (en) 2003-01-28 2004-01-28 Antisense oligonucleotides that inhibit expression of HIF-1
DE602004022921T DE602004022921D1 (de) 2003-01-31 2004-01-28 Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen
CA2513398A CA2513398C (fr) 2003-01-31 2004-01-28 Oligonucleotides anti-sens inhibant l'expression du hif-1
EP04706034A EP1601325B1 (fr) 2003-01-31 2004-01-28 Oligonucleotides anti-sens inhibant l'expression du hif-1
AT04706034T ATE441710T1 (de) 2003-01-31 2004-01-28 Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen
BR0407070-4A BRPI0407070A (pt) 2003-01-31 2004-01-28 Oligonucleotìdeos antisentido que inibem a expressão de hif-1
JP2006503098A JP4546454B2 (ja) 2003-01-28 2004-01-28 Ｈｉｆ−１発現を抑制するアンチセンスオリゴヌクレオチド

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76618503A 2003-01-28 2003-01-28
US10/766,185 2003-01-28
US44436703P 2003-01-31 2003-01-31
US60/444,367 2003-01-31

Publications (3)

Publication Number Publication Date
WO2004066949A2 WO2004066949A2 (fr) 2004-08-12
WO2004066949A8 WO2004066949A8 (fr) 2004-11-11
WO2004066949A3 true WO2004066949A3 (fr) 2005-12-01

Family

ID=32829853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/002344 WO2004066949A2 (fr) 2003-01-28 2004-01-28 Oligonucleotides anti-sens inhibant l'expression du hif-1

Country Status (3)

Country Link
JP (1) JP4546454B2 (fr)
AU (1) AU2004207576B8 (fr)
WO (1) WO2004066949A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014504501A (ja) 2010-12-30 2014-02-24 サムヤン バイオファーマシューティカルズ コーポレイション Ｈｉｆ１αの発現を阻害するｓｉＲＮＡおよびこれを含む抗癌組成物
KR20150020180A (ko) * 2012-05-23 2015-02-25 더 오하이오 스테이트 유니버시티 안티센스 올리고뉴클레오티드 전달을 위한 지질 나노입자 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101858A1 (en) * 2002-11-23 2004-05-27 Isis Pharmaceuticals Inc. Modulation of hypoxia-inducible factor 1 alpha expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
DE60027719T2 (de) * 1999-06-14 2007-04-26 Cancer Research Technology Ltd. Krebstherapie
AU2002231223A1 (en) * 2000-10-26 2002-05-06 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
AU2003225495B2 (en) * 2002-04-05 2009-01-15 Roche Innovation Center Copenhagen A/S Oligomeric compounds for the modulation HIF-1alpha expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101858A1 (en) * 2002-11-23 2004-05-27 Isis Pharmaceuticals Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US20040220393A1 (en) * 2002-11-23 2004-11-04 Ward Donna T. Modulation of HIF1alpha and HIF2alpha expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1601325A4 *

Also Published As

Publication number Publication date
JP4546454B2 (ja) 2010-09-15
JP2006520195A (ja) 2006-09-07
AU2004207576B2 (en) 2008-10-23
AU2004207576A1 (en) 2004-08-12
WO2004066949A2 (fr) 2004-08-12
WO2004066949A8 (fr) 2004-11-11
AU2004207576B8 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
AU2003290598A1 (en) Modified oligonucleotides for use in rna interference
WO2007031319A8 (fr) Compositions comprenant des oligonucleotides d'arn a immunostimulation et procedes pour produire lesdits oligonucleotides d'arn
WO2003064625A3 (fr) Compositions oligonucleotidiques presentant une efficacite amelioree
GB2424887B (en) Sequence-specific inhibition of small RNA function
WO2005079397A3 (fr) Molecules d'oligonucleotides anti-microarn
WO2004092191A3 (fr) Promedicaments oligonucleotidiques polymeres
AU2003237249A1 (en) Oligonucleotides having modified nucleoside units
WO2005118824A3 (fr) Methodes et compositions inhibant l'expression genique
WO2004016215A3 (fr) Utilisation d'oligonucleotides antisens pour inhiber l'expression de akt-1
GB0215534D0 (en) Selective photochemotherapy using oligonucleotide targeting agents
ATE441710T1 (de) Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen
IL171968A0 (en) Difluoromethylbenzanilides and use thereof for combating micro-organisms, intermediate products and use thereof
AU2003279509A8 (en) Targeted double stranded rna mediated cell killing
AU2003242678A1 (en) Antisense oligonucleotides against pim1
IL178764A0 (en) ANTISENSE OLIGONUCLEOTIDES AGAINST cPLA2, COMPOSITIONS AND USES THEREOF
WO2004066949A3 (fr) Oligonucleotides anti-sens inhibant l'expression du hif-1
WO2007065017A3 (fr) Systeme d'administration de liposomes cationiques a oligonucleotides
AP2006003512A0 (en) Woos treating formulation.
AU2003292227A1 (en) Combined antisense oligonucleotide cancer therapy
IL182280A0 (en) Single stranded antimicrobial oligonucleotides and uses thereof
WO2005025487A3 (fr) Oligonucleotides ciblant les maladies a prions
AU2002236489A1 (en) Reduction of antioxidant enzyme levels in tumor cells using antisense oligonucleotides
WO2003074060A8 (fr) Combinaison chimiothérapie et antisens de la dna déméthylase
AU2003247521A1 (en) Antisense inhibition via rnase h-independent reduction in mrna
AU2003218555A1 (en) Combinations of antisense oligonucleotides directed against thymidylate synythase mrna and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 33/2004 UNDER (30) DELETE "10/766,18, 28 JANUARY 2003 (28.01.2003), US"

WWE Wipo information: entry into national phase

Ref document number: 2513398

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004207576

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020057013673

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006503098

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20048032331

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004706034

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004207576

Country of ref document: AU

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 1020057013673

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004706034

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0407070

Country of ref document: BR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载